Results 41 to 50 of about 19,293 (297)

Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies

Journal of Clinical Medicine, 2022
Peritoneal carcinomatosis (PC) is a poor prognostic factor for all malignancies. This extent of metastatic disease progression remains difficult to treat with systemic therapies due to poor peritoneal vascularization resulting in limited drug delivery ...
Megan M Harper, Joseph J Kim, P. Pandalai   +2 more
semanticscholar   +1 more source

Assessment of Hyperthermic Intraperitoneal Chemotherapy to Eradicate Intraperitoneal Free Cancer Cells

Translational Oncology, 2016
OBJECTIVE: To assess the effect of hyperthermic intraperitoneal chemotherapy (HIPEC) to eradicate intraperitoneal free cancer cells and to explore the feasibility of cytological cure for peritoneal carcinomatosis (PC).
Zhonghe Ji, Jianhua Sun, Haitao Wu, Qian Zhang, Kaiwen Peng, Yan Li   +5 more
doaj   +1 more source

Anastomosis versus rectal stump procedure in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal peritoneal metastases: A comparative study. [PDF]

Colorectal Dis
Abstract Aim Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is the standard treatment for peritoneal metastases (PM) of colorectal or appendiceal origin. Rectal anastomotic leakage (RAL) or rectal stump blow‐out is a serious complication following rectal resection after CRS‐HIPEC. This study aimed to compare outcomes
Ghanipour L, Mahmmud LO, Cashin P, Palmer GJ, Abraham-Nordling M.   +4 more
europepmc   +2 more sources

Intraperitoneal chemotherapy for peritoneal metastases : an expert opinion

, 2020
Introduction: The rationale for intraperitoneal (IP) drug delivery for patients with peritoneal metastases (PM) is based on the pharmacokinetic advantage resulting from the peritoneal-plasma barrier, and on the potential to adequately treat small, poorly
Braet, Helena, Ceelen, Wim, Remaut, Katrien, Van Ramshorst, Gabrielle, Willaert, Wouter   +4 more
core   +1 more source

The Global End-Diastolic Volume (GEDV) Could Be More Appropiate to Fluid Management Than Central Venous Pressure (CVP) During Closed Hyperthermic Intrabdominal Chemotherapy with CO2 Circulation

Journal of Investigative Surgery, 2018
Background: Closed hyperthermic intraperitoneal chemotherapy (HIPEC) may increase abdominal pressure and effects of hemodynamic changes due to maintenance hyperthermia.
Francisco Javier Redondo, David Padilla, Pedro Villarejo, Victor Baladron, Patricia Faba, Sergio Sánchez, José Ramón Muñoz-Rodríguez, Natalia Bejarano   +7 more
doaj   +1 more source

The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis

Journal of Ovarian Research, 2019
Background and objective Previous studies about the prognostic value of the HIPEC have yielded controversial results. Therefore, this study aims to assess the impact of HIPEC on patients with ovarian cancer.
Guyu Zhang, Yimin Zhu, Chongdong Liu, Guangming Chao, Ran Cui, Zhenyu Zhang   +5 more
doaj   +1 more source

Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]

, 2018
Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B., Katz, Steven C., Khalili, Marian, Morano, William F., Richard, Scott D., Thadi, Anusha   +5 more
core   +2 more sources

Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma – the phase III “PREVENT”- (FLOT9) trial of the AIO /CAOGI /ACO

BMC Cancer, 2021
The main reason for treatment failure after curative surgical resection of gastric cancer is intra-abdominal spread, with 40–50% peritoneal seeding as primary localization of recurrence.
T. Goetze, P. Piso, S. Lorenzen, U. Bankstahl, C. Pauligk, Moustafa Elshafei, G. Amato, D. Reim, W. Bechstein, A. Königsrainer, S. Mönig, B. Rau, M. Schwarzbach, S. Al-Batran   +13 more
semanticscholar   +1 more source

Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial

International Journal of Gynecological Cancer, 2020
Background The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improves recurrence-free and overall survival in patients with FIGO stage III ovarian cancer who are ineligible for primary cytoreductive ...
S. Koole, R. V. van Stein, K. Sikorska, D. Barton, L. Perrin, D. Brennan, O. Zivanovic, B. Mosgaard, A. Fagotti, Pierre-Emmanuel Colombo, G. Sonke, W. J. V. Driel   +11 more
semanticscholar   +1 more source

Peritoneal carcinomatosis [PDF]

, 2013
Several gastrointestinal and gynecological malignancies have the potential to disseminate and grow in the peritoneal cavity. The occurrence of peritoneal carcinomatosis (PC) has been shown to significantly decrease overall survival in patients with liver
Ansaloni L, BAIOCCHI, Gian Luca, Catena F., Coccolini F, Ghermandi C, GHEZA, Federico, GIULINI, Stefano Maria, Iusco D, Lotti M, Melotti R, Virzì S   +10 more
core   +1 more source